Tag: price

XRP cloud mining platform offers both fixed returns and crypto appreciation amid renewed investor interest

TALLINN, Estonia, July 19, 2025 (GLOBE NEWSWIRE) -- With the cryptocurrency market facing renewed volatility, investors are seeking solid opportunities with long-term potential. Bitcoin Solaris (BTC-S), an emerging blockchain project, is capturing attention for all the right reasons. As it nears the end of its presale phase, Bitcoin Solaris offers a guaranteed launch price of $20—positioning itself as a secure and forward-looking investment in uncertain times.

Why Bitcoin Solaris Stands Out from the Rest

LUXEMBOURG, July 19, 2025 (GLOBE NEWSWIRE) -- Bitcoin Swift(BTC3), a next-generation digital asset protocol, today announced the official launch of Stage 1 of its public presale, offering early participants programmable mining rewards without the need for staking or lock-ups. The launch marks a significant step forward in blockchain evolution by introducing an AI-enhanced Proof-of-Yield (PoY) system that dynamically rewards network contributors in real time.

Chicago, Illinois, July 18, 2025 (GLOBE NEWSWIRE) -- Ripple (XRP) has broken through its historical price high, triggering a market boom again. At this critical moment, RICH Miner, a leading cloud computing platform, has launched a new "XRP Mobile Mining" service, opening up a low-threshold, anytime passive income path for XRP holders around the world.

SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Neogen Corporation (NASDAQ: NEOG) common stock between January 5, 2023 and June 3, 2025, inclusive (the “Class Period”), have until September 16, 2025 to seek appointment as lead plaintiff of the Neogen class action lawsuit. Captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. Neogen Corporation, No. 25-cv-00802 (W.D. Mich.), the Neogen class action lawsuit charges Neogen and certain of Neogen’s top executives with violations of the Securities Exchange Act of 1934.

SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 17, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 138,190 shares of Iovance’s common stock to 20 new, non-executive employees.